Our CEO, Dr Keith Martin, and Commercial Director, Dr Hayley French, will be attending the Jefferies 2016 London Healthcare Conference from 15 to 17 November. They will be available to meet with you during the conference to discuss potential business relationships.
Our commercial director and general counsel, Dr. Hayley French and research director, Dr Lotta Jansson will be participating in the Bio-Europe partnering conference to be held November 7th – 9th in Cologne, Germany. They look forward to meeting with you to discuss potential partnerships.
Prof. David Wraith, Apitope’s founder and CSO, will be presenting at the FOCIS annual meeting, to be held during June 22-25th being held in the Seaport and World Trade Centre Hotel in Boston, USA. David will be giving a presentation titled “Switching off unwanted immune responses: the mechanism of antigen-specific immunotherapy with T cell epitopes”.
For more details about the conference visit: http://www.focisnet.org/2013-03-07-14-01-50/2015-annual-meeting
Apitope’s commercial director and general counsel, Dr. Hayley French will be attending the BIO International Convention, to be held June 6th – 9th in the Moscone Convention Centre in San Francisco, USA. Hayley will be participating in the partnering sessions and is looking forward to meeting with you to discuss potential partnerships.
For more details about the convention, please visit BIO International’s website: http://convention.bio.org/
Our commercial director and general counsel, Dr. Hayley French and research director, Dr Lotta Jansson will be participating in the Bio-Europe Spring partnering conference to be held April 4th – 6th in Stockholm, Sweden. They look forward to meeting with you to discuss potential partnerships.
For more information, please visit the conference website: http://www.ebdgroup.com/bes/index.php
Prof. David Wraith, Apitope’s founder and CSO, will be presenting at the Mastering Immunity Europe conference, being held on March 21st in Oxford, UK. David will be giving a presentation titled “Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”.
For more details about the conference, please visit Mastering Immunity’s website: https://www.proimmune.com/ecommerce/page.php?page=MIE2016
Cardiff, UK and Hasselt, Belgium: 9 May 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that Dr Keith Martin, CEO of Apitope, is scheduled to present at Bio€quity Europe on Tuesday, 10 May 2016 at 2.20 pm CET at the Scandic Hotel, Copenhagen, Denmark.
Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.
Apitope’s research director, Lotta Jansson will be presenting at the EAHAD conference.
For further information please see: http://www.eahad2016.com/
Apitope’s commercial director & general counsel will be attending the JP Morgan conference in San Francisco during 11th-14th January 2016. Please contact Hayley.french@apitope for further information.
Apitope will be attending the Genesis conference in London on the 10th December 2015 and CEO, Keith Martin will be speaking on the panel session “international growth strategies in Europe”.
For further information please see: http://www.genesisconference.com/programme-2015/